Literature DB >> 31858560

CircRNA_0016418 expedites the progression of human skin melanoma via miR-625/YY1 axis.

Y Zou1, S-S Wang, J Wang, H-L Su, J-H Xu.   

Abstract

OBJECTIVE: Some circular RNAs (circRNAs) have been testified to play crucial roles in the regulation of skin melanoma, including circRNA_0016418 (circ0016418). However, the regulatory mechanism of circ0016418 in skin melanoma is undiscovered.
MATERIALS AND METHODS: The RNA expression was examined through quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and associated-proteins levels were measured via Western blot. Cell counting kit-8 (CCK-8) assay was used for detecting cell proliferation. Transwell assay was conducted to assess the abilities of migration and invasion. The target relation was analyzed by Dual-Luciferase reporter assay.
RESULTS: The levels of circ0016418 and Yin Yang 1 (YY1) were up-regulated in skin melanoma tissues and cells. Knockdown of both circ0016418 and YY1 had suppressive effects on proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of skin melanoma cells. YY1 overexpression reverted the inhibitory effects on skin melanoma cells caused by circ0016418 knockdown. Circ0016418 negatively modulated microRNA-625 (miR-625) expression and miR-625 directly targeted YY1. Circ0016418 functioned as a competitive endogenous RNA (ceRNA) of miR-625 to regulate YY1 expression.
CONCLUSIONS: Circ0016418 regulated proliferation, migration, invasion, and EMT of skin melanoma cells through miR-625/YY1 axis. Circ0016418 might be a useful indicator of the therapeutic strategies of skin melanoma.

Entities:  

Year:  2019        PMID: 31858560     DOI: 10.26355/eurrev_201912_19795

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  Circular RNA as a Potential Biomarker for Melanoma: A Systematic Review.

Authors:  Keyun Tang; Hanlin Zhang; Yaqi Li; Qiuning Sun; Hongzhong Jin
Journal:  Front Cell Dev Biol       Date:  2021-04-01

2.  CircularRNA_0119872 regulates the microRNA-582-3p/E2F transcription factor 3 pathway to promote the progression of malignant melanoma.

Authors:  Jinlong Qu; Chunying Yuan; Qi Jia; Mengwei Sun; Min Jiang; Fuguang Zuo
Journal:  Clinics (Sao Paulo)       Date:  2021-10-11       Impact factor: 2.365

Review 3.  Crucial Roles of miR-625 in Human Cancer.

Authors:  Menggang Zhang; Fei Xiong; Shuijun Zhang; Wenzhi Guo; Yuting He
Journal:  Front Med (Lausanne)       Date:  2022-03-04

4.  Oncogenic circular RNA circ_0007534 contributes to paclitaxel resistance in endometrial cancer by sponging miR-625 and promoting ZEB2 expression.

Authors:  Hanjie Yi; Yongqing Han; Shanfeng Li
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

Review 5.  Non-coding RNAs in skin cancers:Biological roles and molecular mechanisms.

Authors:  Fei Liu; Shenglong Li
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

Review 6.  Squaring the circle: circRNAs in melanoma.

Authors:  Nicol Mecozzi; Olga Vera; Florian A Karreth
Journal:  Oncogene       Date:  2021-07-30       Impact factor: 9.867

7.  Circ_0013359 facilitates the tumorigenicity of melanoma by regulating miR-136-5p/RAB9A axis.

Authors:  Qi Zhang; Yingfa Feng; Jiangang Feng; Jinming Zhang; Lili Huang
Journal:  Open Life Sci       Date:  2021-05-22       Impact factor: 0.938

Review 8.  The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma.

Authors:  Barbara Montico; Giorgio Giurato; Giovanni Pecoraro; Annamaria Salvati; Alessia Covre; Francesca Colizzi; Agostino Steffan; Alessandro Weisz; Michele Maio; Luca Sigalotti; Elisabetta Fratta
Journal:  Mol Oncol       Date:  2021-06-18       Impact factor: 6.603

Review 9.  Roles Played by YY1 in Embryonic, Adult and Cancer Stem Cells.

Authors:  Gustavo Ulises Martinez-Ruiz; Abigail Morales-Sanchez; Angel Francisco Pacheco-Hernandez
Journal:  Stem Cell Rev Rep       Date:  2021-03-17       Impact factor: 5.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.